LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)
-
Upload
pharmacoserias -
Category
Health & Medicine
-
view
233 -
download
0
Transcript of LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)
![Page 1: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/1.jpg)
![Page 2: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/2.jpg)
![Page 3: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/3.jpg)
![Page 4: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/4.jpg)
![Page 5: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/5.jpg)
![Page 6: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/6.jpg)
Nace Arequipa Dr.Max Glez.Olaechea 1er latino Miembro Honor American Academy of Medicine,Ny
-”Pioneros…”
![Page 7: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/7.jpg)
F.Lesseps: Concesión Canal Suez
Nace Arequipa Dr.Max Glez.Olaechea 1er latino Miembro Honor American Academy of Medicine,Ny
-”Pioneros…”
-”Luchar…”
![Page 8: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/8.jpg)
Nace Arequipa Dr.Max Glez.Olaechea 1er latino Miembro Honor American Academy of Medicine,Ny
F.Lesseps: Concesión Canal Suez
-”Pioneros…”
-”Luchar…”
-”Perseverar…”
USA/URRS inician acuerdo armas nucleares (Ginebra)
![Page 12: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/12.jpg)
![Page 13: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/13.jpg)
La farmacia más antigua de Asturias está en Cangas de Onís (1.891)
![Page 14: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/14.jpg)
![Page 15: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/15.jpg)
![Page 16: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/16.jpg)
![Page 17: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/17.jpg)
![Page 18: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/18.jpg)
“Un mensaje que uno envía siempre conlleva una
inclinación peligrosa a convertirse en una orden”
“El mensaje encierra un intento de coaccionar, de
“informar”, de darle una cierta forma al otro, de que yo me
convenza de su razón”
Prof. A.Pasquali UCV Caracas Vzla.
La Nueva España 13/01/2008
![Page 19: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/19.jpg)
![Page 20: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/20.jpg)
![Page 21: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/21.jpg)
![Page 22: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/22.jpg)
Se acabó...
![Page 23: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/23.jpg)
Medicalización
![Page 24: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/24.jpg)
“Hace mas de treinta años Henry Gadsden, entonces
director de la compañía farmacéutica Merck, realizó a la
revista Fortune unas declaraciones sorprendentes y en
cierto modo ingenuas. Dijo que su sueño era llegar a
producir medicamentos para las personas sanas y así
promover un amplio mercado de consumidores.”
![Page 25: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/25.jpg)
“La medicina ha avanzado tanto que ya
nadie está sano” Aldous Huxley
![Page 26: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/26.jpg)
« les gens bien portants sont
des malades qui s'ignorent »
“Toda persona sana
es un enfermo
que ignora que lo es”
![Page 27: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/27.jpg)
Medicalización “La forma en que el ámbito
de la medicina se ha expandido
en los años recientes y ahora
abarca muchos problemas
que antes no estaban definidos
como entidades médicas” Kishore 2002. Diccionario de Salud Pública
![Page 28: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/28.jpg)
Medicalización
![Page 29: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/29.jpg)
“ La medicina institucionalizada amenaza la salud”.
Iván Illich Némesis Médica 1974
Iván Illich I. L’obsession de la santé parfaite.
“ En los países desarrollados la obsesión por una Salud perfecta se ha convertido en el factor patógeno predominante”
![Page 30: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/30.jpg)
Medicalización
![Page 31: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/31.jpg)
Medicalización
![Page 32: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/32.jpg)
Medicalización
![Page 33: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/33.jpg)
Medicalización
![Page 34: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/34.jpg)
Medicalización
![Page 35: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/35.jpg)
"Aceite de oliva ecológico
que combate los síntomas
de la menopausia" Medicalización
![Page 36: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/36.jpg)
Medicalización
![Page 37: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/37.jpg)
Medicalización
![Page 38: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/38.jpg)
Medicalización
![Page 39: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/39.jpg)
![Page 40: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/40.jpg)
![Page 41: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/41.jpg)
“Las personas y la sociedad se
hacen así dependientes de la
medicina y los servicios
sanitarios, que necesitarán cada
vez más recursos para dar
respuesta a la demanda que va
induciendo”.
![Page 42: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/42.jpg)
La medicalización nos lleva a un modelo
sanitario caro, con grandes costes que
puede poner en peligro la sostenibilidad
de la cobertura universal.
![Page 43: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/43.jpg)
Premio Nobel
Economía (1998)
A más dinero tiene una
sociedad (y más gasto
sanitario), mayor número
de ciudadanos se
consideran enfermos.
Health: perception versus observation.
BMJ 2002;324: 860-1
Amartya Kumar Sen *1933
(India)
![Page 44: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/44.jpg)
El economista Uwe Reinhardt sugería
irónicamente que si el consumo
sanitario seguía aumentando, EE.UU.
sería como un gran hospital, donde la
población estaría formada por
trabajadores de la salud, enfermos, o
ambas cosas al tiempo.
Reinhardt U. Response to “What can Americas learn from Europeans”
En Health Care Systems in Transition: The Search for Efficiency,
OECD. Paris, 1990.
![Page 45: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/45.jpg)
![Page 46: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/46.jpg)
![Page 47: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/47.jpg)
![Page 48: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/48.jpg)
![Page 49: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/49.jpg)
![Page 50: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/50.jpg)
![Page 51: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/51.jpg)
![Page 52: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/52.jpg)
![Page 53: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/53.jpg)
![Page 54: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/54.jpg)
![Page 55: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/55.jpg)
![Page 56: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/56.jpg)
![Page 57: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/57.jpg)
![Page 58: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/58.jpg)
![Page 59: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/59.jpg)
Dr. Drauzio Varella,
Oncologo, escritor.
Universidad Paulista/Brasil
![Page 60: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/60.jpg)
![Page 61: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/61.jpg)
•Los profesionales y sus instituciones
•Las empresas médico-farmacéuticas •Los medios de comunicación
•La población
•La Administración y los gestores de servicios sanitarios
LOS PROTAGONISTAS
DE LA MEDICALIZACIÓN
![Page 62: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/62.jpg)
Medicalización
“Big Pharma”
![Page 63: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/63.jpg)
*Megamergers Status Actual…
VENTAS
I+D
![Page 64: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/64.jpg)
![Page 65: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/65.jpg)
![Page 66: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/66.jpg)
![Page 67: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/67.jpg)
![Page 68: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/68.jpg)
![Page 69: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/69.jpg)
![Page 70: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/70.jpg)
"Pharmaceutical companies
are not as important
as the local chains of
distribution here.
This area of the business
also poses itself as a challenge,
particularly with pharmacy chains
and their high expectations
in terms of commercial
aggressiveness
on the industry toward them."
Rodrigo Fernandez,
country president of AstraZeneca’s
CAMCARMAC region
![Page 71: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/71.jpg)
![Page 72: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/72.jpg)
![Page 73: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/73.jpg)
![Page 74: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/74.jpg)
March 2003
![Page 75: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/75.jpg)
2000
![Page 76: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/76.jpg)
2002
2005
![Page 77: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/77.jpg)
2006
![Page 78: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/78.jpg)
![Page 79: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/79.jpg)
![Page 80: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/80.jpg)
![Page 81: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/81.jpg)
![Page 82: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/82.jpg)
http://bit.ly/2gj2Twk
![Page 83: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/83.jpg)
![Page 84: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/84.jpg)
Las farmacéuticas
Pfizer (Viagra) y Allergan (Botox)
estudian fusionarse
![Page 85: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/85.jpg)
*Megamergers
VENTAS
*Alianzas estratégicas Status Actual…
![Page 86: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/86.jpg)
![Page 87: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/87.jpg)
The startup has been backed by a number of big
players in the industry:
the company’s financing was co-led by
RiverVest Venture Partners and venture
divisions of major pharma firms
Novo Nordisk, Roche and GSK.
anti-CD47
immune checkpoint inhibitor
![Page 88: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/88.jpg)
![Page 89: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/89.jpg)
![Page 90: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/90.jpg)
![Page 91: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/91.jpg)
*Megamergers
*Alianzas estratégicas
Venta$
Consumo
CONTROL Rx
Precios
Status Actual…
*”Estagnación”
COSTOS
DIFICULTAD INTRODUCCION
NUEVOS PRODUCTOS
![Page 92: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/92.jpg)
Otras
Cías.
BENEFICIO$
RENTABILIDAD
Market Share
Conocimiento Competencia
Market Growth
Key Pharmaceutical Markets: VENTAS < 10%
(+ x Precio)
![Page 93: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/93.jpg)
CUSTOMER DRIVEN COMPETITOR DRIVEN
EVOLUCION INDUSTRIA
FARMACEUTICA EVOLUCION INDUSTRIA
FARMACEUTICA
![Page 94: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/94.jpg)
MARKETING MANAGER
TASK
* Estudio de competencia
* Identificación debilidades
* Diseño de estrategia competitiva
![Page 95: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/95.jpg)
Benchmarking (Referenciación)
Técnica de gestión empresarial que compara
los niveles de eficiencia de la propia
organización con estándares externos
con el propósito de realizar mejoras.
![Page 96: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/96.jpg)
![Page 97: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/97.jpg)
![Page 98: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/98.jpg)
![Page 99: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/99.jpg)
•price pressures on drugs,
•increasing R&D cost,
•a risk-averse regulatory environment and
•more aggressive generic competitors
“the increasingly challenging industry conditions –
including continuous
Daniel Vasella /Novartis CEO Basel, Dec 13, 2007
![Page 100: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/100.jpg)
![Page 101: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/101.jpg)
![Page 102: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/102.jpg)
![Page 103: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/103.jpg)
Precios…
![Page 104: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/104.jpg)
Obsolescencia
![Page 105: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/105.jpg)
![Page 106: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/106.jpg)
![Page 107: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/107.jpg)
![Page 108: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/108.jpg)
![Page 109: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/109.jpg)
30-OCT-2011
![Page 110: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/110.jpg)
“entre 1995 y 2002 la industria farmacéutica fue la más
rentable de EE.UU., en términos de beneficio neto medio
después de impuestos como porcentaje de los ingresos.
El 2003 decayó un poco (...) pero mantuvo un margen de rentabilidad del 14%, tres veces superior a la media de todas las empresas incluidas aquel año en la lista Fortune 500”.
Informe 2006 (OMS)
Comisión Salud Pública/
Innovación y Derechos de
Propiedad Intelectual
![Page 111: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/111.jpg)
![Page 112: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/112.jpg)
Dr. Eduardo Espinoza, Viceministro de Salud El Salvador
![Page 113: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/113.jpg)
![Page 114: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/114.jpg)
![Page 115: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/115.jpg)
![Page 116: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/116.jpg)
![Page 117: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/117.jpg)
![Page 118: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/118.jpg)
![Page 119: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/119.jpg)
Martin Shkreli of
Turing Pharmaceuticals
raised the price for Daraprim
by 5,455%
![Page 120: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/120.jpg)
“Creo que podría haberlo subido aún más y
haber sacado más beneficio.
Nuestros accionistas esperan que hagas todo el
dinero posible.
Ésa es la fea verdad.
Es parte de lo que la
America capitalista significa.“ Forbes Healthcare Summit
![Page 121: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/121.jpg)
“Our shareholders expect
you should
make as much money
as possible —
that’s
the ugly truth,”
![Page 122: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/122.jpg)
“la sociedad no te puede meter en la cárcel
por violar tu responsabilidad fiduciaria“/
“I know society can’t put you
in jail for violating
your fiduciary responsibility,”
![Page 123: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/123.jpg)
![Page 124: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/124.jpg)
![Page 125: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/125.jpg)
http://ti.me/2bDaKPH
![Page 126: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/126.jpg)
Sarah Jessica Parker
http://bit.ly/2fYa3BW
![Page 127: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/127.jpg)
![Page 128: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/128.jpg)
![Page 129: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/129.jpg)
![Page 130: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/130.jpg)
![Page 131: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/131.jpg)
![Page 132: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/132.jpg)
![Page 133: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/133.jpg)
"Price is the
wrong
discussion,"
Gilead Sciences' executive vice
president, Gregg Alton,
![Page 134: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/134.jpg)
![Page 135: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/135.jpg)
![Page 136: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/136.jpg)
![Page 137: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/137.jpg)
![Page 138: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/138.jpg)
![Page 139: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/139.jpg)
![Page 141: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/141.jpg)
Precios
R&D…
![Page 142: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/142.jpg)
![Page 143: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/143.jpg)
![Page 144: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/144.jpg)
Record Numbers of
FDA-Approved Drugs:
Recent Trends
March 10, 2016
![Page 145: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/145.jpg)
![Page 146: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/146.jpg)
Desarrollar un medicamento cuesta 897 mio $ y desde el descubrimiento hasta la
venta se tardan entre 10 y 15 años.
Tufts Center for the Study of Drug Development de Boston
![Page 147: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/147.jpg)
“Dijeron que costaba 802 mio de $
sacar un medicamento.
Sin embargo, estaban analizando los
fármacos cuyo desarrollo resulta más caro.
La mayoría de los fármacos nuevos no lo
son.
Se trata de los llamados fármacos
”me too…”
![Page 148: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/148.jpg)
-“Me too”
“no brindan una ventaja significativa, pero
son lo suficientemente distintos para
merecer una patente y salir al mercado,
generalmente a un precio idéntico al
del producto original, o quizás mas alto”
![Page 149: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/149.jpg)
“Developing drugs
takes a very long time:
From discovery all the way to
launch could be 10 or 12 years and
cost almost $2 billion.”
Joe Jimenez CEO Novartis
NOVEMBER 15, 2011
![Page 150: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/150.jpg)
Publicado (7 February 2011)
London School of Economics and Political Science
![Page 151: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/151.jpg)
Big Pharma did not invent these lifesaving drugs that they have patented and arbitrarily overpriced, incidentally. Anti-retrovirals were for the most part discovered by publicly funded US research projects into other diseases, and only later entrusted to pharmaceutical companies for marketing and exploitation.
IN PLACE OF NATIONS
by John Le Carre
![Page 152: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/152.jpg)
Extension de
las patentes (Glivec,
Viagra…)
Derivación/ Extensión a
Genéricos, (Sandoz, …
Megafusiones
Merck&Schering,
Pfizer&Wyeth
Compra de empresas
de I+D
Roche/
Genentech
BIG PHARMA: Respuesta al “Dry Pipeline”
![Page 153: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/153.jpg)
Collaboration can play an
important role in accessing the external
capabilities that will be required
ViiV Healthcare,
a joint venture between
Pfizer and
GlaxoSmithKline (GSK)
in the development of HIV treatment.
Besides the fact that two businesses that are typically competitors are
working together, this partnership is notable in that it is continuing the
not-for-profit pricing schemes that Pfizer and GSK had already started,
and is covering low and middle-income countries, including the whole
of sub-Saharan Africa.
![Page 154: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/154.jpg)
Pfizer is making a big push into oncology for
several reasons.
Discoveries in immunology and genetics are
allowing for the development of much more
effective drugs, many of which sell for well
over $100,000 a year.
![Page 155: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/155.jpg)
![Page 156: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/156.jpg)
![Page 157: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/157.jpg)
![Page 158: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/158.jpg)
http://bit.ly/2g1gi9T
![Page 159: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/159.jpg)
Whether peak annual Humira sales will ever reach the Lipitor
benchmark is open to conjecture.
Current consensus forecasts indicate that sales of the anti-TNF
product will peak at $11.2 billion in 2016
Top 25 pharmaceutical products 2015
http://bit.ly/2f7bb95
![Page 160: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/160.jpg)
http://bit.ly/1T9usD6
![Page 161: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/161.jpg)
![Page 162: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/162.jpg)
![Page 163: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/163.jpg)
![Page 164: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/164.jpg)
![Page 165: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/165.jpg)
De la polimedicación
a la poli_APP_licación...
![Page 166: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/166.jpg)
![Page 167: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/167.jpg)
http://bit.ly/1mkr0EJ
![Page 168: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/168.jpg)
![Page 169: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/169.jpg)
http://bit.ly/1e2q4CO
![Page 170: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/170.jpg)
![Page 171: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/171.jpg)
Life sciences Performing
in the Downturn
and Beyond
CapGemini
“Companies across the industry
have come to realize that
their current cost structures
are simply not sustainable
in the long term.”
![Page 172: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/172.jpg)
“The existing business models
of big pharma, speciality and generics,
are not well adapted to these new habitats.
Today's firms will therefore adapt or die…”
![Page 173: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/173.jpg)
![Page 174: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/174.jpg)
![Page 175: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/175.jpg)
![Page 176: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/176.jpg)
![Page 177: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/177.jpg)
![Page 178: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/178.jpg)
Percent of Revenue Allocated to:
Company Revenue (Millions)
Marketing
Advert/Admin.
R&D
Profits Merck & Co. $47,716 13% 5% 15%
Pfizer $32,259 35% 15% 24%
BMS $19,423 27% 12% 27%
Abbott Labs $16,285 23% 10% 10%
Wyeth $14,129 37% 13% 16%
Pharmacia $13,837 44% 16% 11%
Eli Lilly & Co $11, 543 30% 19% 24%
2001 Financials for U.S. Corporations Families USA, 2002
![Page 179: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/179.jpg)
Design critique: Putting Big Pharma
spending in perspective March 1, 2015
![Page 180: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/180.jpg)
![Page 181: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/181.jpg)
![Page 182: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/182.jpg)
![Page 183: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/183.jpg)
![Page 184: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/184.jpg)
![Page 185: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/185.jpg)
![Page 186: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/186.jpg)
![Page 187: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/187.jpg)
![Page 188: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/188.jpg)
![Page 189: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/189.jpg)
![Page 190: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/190.jpg)
![Page 191: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/191.jpg)
![Page 192: LatFar: Panorama Global de la Industria Farmacéutica/Oportunidades de desarrollo (I)](https://reader036.fdocuments.in/reader036/viewer/2022070509/589b94c21a28abc0098b6d35/html5/thumbnails/192.jpg)
Santander | 18/06/2008
Richard Smith